CHINA MERCHANTS (00133) announced that its wholly-owned subsidiary, Shenzhen Tianzheng Investment Co., Ltd., entered into a share purchase agreement and related agreements on October 28, 2025, regarding Borui Kang Technology (Shanghai) Co., Ltd. Tianzheng agreed to invest RMB 15 million in Borui Kang Technology as part of its Series E financing. The investment was completed on November 7, 2025.

Founded in November 2011, Borui Kang Technology is a high-tech enterprise specializing in brain-computer interface (BCI) systems. The company focuses on R&D, production, sales, and technical services related to BCI devices. With years of dedicated research in the field, Borui Kang has accumulated extensive technical expertise and device development experience.

Borui Kang's products are widely applied in neuroscience, psychology, human factors engineering, kinesiology, and management research, as well as clinical fields such as neurological disease diagnosis, treatment, and rehabilitation. Its innovations and technological capabilities have gained recognition from experts in neuroengineering and clinical medicine globally.

CHINA MERCHANTS believes this investment will enhance the proportion of healthcare-related projects in its portfolio, further optimizing its investment strategy.